FDA
FDA signals openness to potential expansion of testosterone therapy labeling
Testosterone replacement therapy (TRT) has long been reserved for men with hypogonadism linked to clear genetic or structural causes. In a new regulatory step, the FDA is signaling openness to reevaluating that boundary as emerging data suggest a subset of men outside current labeling may benefit.
In an April 16, 2026 press release, FDA announced it is encouraging manufacturers of FDA‑approved TRT products to contact the agency if they are interested in pursuing a potential new indication for low libido in men with idiopathic hypogonadism, defined as low testosterone levels without an identifiable cause. This follows a preliminary FDA review of published clinical literature and discussion during an expert panel meeting held in December 2025.
Currently, all TRT products are approved only for men with hypogonadism due to known congenital or acquired conditions. The agency emphasized that this announcement does not change existing indications. Any expansion would require submission of a supplemental new drug application and demonstration of substantial evidence that benefits outweigh risks for the intended population.
“New and emerging data suggest there may be an opportunity to help men suffering from symptoms that significantly affect quality of life,” said FDA Commissioner Marty Makary, MD, MPH. “We are eager to work with sponsors to further evaluate this potential new use while upholding our rigorous standards for safety and effectiveness.”